Diclofenac Immediate Release for Migraine and short-term acute pain Treatment

DICLOFENAC IMMEDIATE RELEASE

Diclofenac is a non-steroidal anti-inflammatory drug (NSAID), indicated for the management of short-term acute painful conditions.

Post-traumatic inflammation (e.g. sprains)

Post-operative inflammation

Following dental procedures/orthopedic surgery

Primary dysmenorrhea

Migraine attacks

Immediate release oral diclofenac (50mg), thanks to its rapid and predictable absorption ensures fast relief of pain to GET over compliance issues. It is available in a range of easy-to-use formulations to suit all types of pain - powder for oral solution (sachets), oral solution/drops and oral tablets.

"Cambia" logo is a registered trademark of Depomed exclusively licensed in USA and Canada.
"Voltfast" logo is a registered trademark of Novartis AG, licensed internationally.

IMMEDIATE RELEASE
TECHNOLOGY

Immediate Release Technology (IRT), developed and patented by APR, is characterized by the unique blending of excipients and in particular a special ratio between diclofenac and bicarbonate, that create a micro-environmental at gastro-intestinal level, to ensure more rapid and regular absorption and faster onset of action of diclofenac in APR formulations (powder for oral solution, tablets and oral solution) compared with conventional preparations.

Advantages of a Immediate Release Technology are:

Immediate and regular absorption

Decreasing in inter-subjects absorption variability

Fast onset of action

Improved efficacy patient compliance

Diclofenac K 50 mg powder
for oral solution (sachets)

The first patented diclofenac (NSAID) formulation for the treatment of acute migraine with/without aura.
Demonstrated superior efficacy and safety compared with conventional diclofenac tablets.
Unique features of diclofenac-K 50mg IR sachet for migraine, mean that it cannot be replaced by other diclofenac/NSAIDs preparations.

Diclofenac potassium

50 mg

Powder for oral solution (sachets)

Prescription

EU and Extra-EU Countries: short term treatment of acute painful and inflammation conditions and migraine attacks
US: acute treatment of migraine attacks with or without aura in adults

Registered and marketed in several EU and Extra-EU countries by Novartis (Voltfast®, Catafast®, Cataflam®).
Registered and marketed in USA by Depomed (CAMBIA®)

Patented

Diclofenac K 50 mg/ml
(5% w/v) oral solution

Immediate release diclofenac available as oral solution (drops) that combines the proven pain-relieving power of diclofenac in a new solution produced using Immediate Release Technology (IRT) that:

ensures fast absorption and
onset of action.

Diclofenac potassium

50 mg/ml

Oral solution

Prescription

Germany:

Acute treatment of migraine attacks with or without aura

Italy:

painful inflammation following trauma, eg . distortions;
inflammation and pain post-surgery, eg. after dental or orthopedic surgery;
primary dysmenorrhea.

Registered and marketed in Germany by TevaRatiopharm (Diclofenac-ratiopharm® Lösung bei Migräne)
Registered and marketed in Italy by Alfa Wassermann (EMINOCS®)

Patented

Diclofenac K 50 mg tablets

Immediate release tablets indicated for pain relief, due to their characteristic faster absorption against the conventional tablets.

Diclofenac potassium

50 mg

Film Coated Tablets

Prescription

Short term treatment of Acute Painful Conditions

Registered and Marketed in Switzerland by Spirig (Inflamac® Rapid) and Helvepharm (Diclofenac rapid Helvepharm)
Registered in India by drReddy’s (Supanac®).
Registered but not marketed in Italy and Sweden.

Patented

Diclofenac K 50 mg powderfor oral solution (sachets)

Diclofenac K 50 mg/ml(5% w/v) oral solution

Diclofenac K 50 mg tablets

Diclofenac K 50 mg powder
for oral solution (sachets)

Diclofenac K 50 mg/ml
(5% w/v) oral solution